Assessment of Long-Term Effects of Irbesartan on Heart Failure With Preserved Ejection Fraction as Measured by the Minnesota Living With Heart Failure Questionnaire in the Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) Trial
Publication
, Journal Article
Rector, TS; Carson, PE; Anand, IS; McMurray, JJ; Zile, MR; McKelvie, RS; Komajda, M; Kuskowski, M; Massie, BM
Published in: Circulation: Heart Failure
March 2012
Duke Scholars
Published In
Circulation: Heart Failure
DOI
EISSN
1941-3297
ISSN
1941-3289
Publication Date
March 2012
Volume
5
Issue
2
Start / End Page
217 / 225
Publisher
Ovid Technologies (Wolters Kluwer Health)
Related Subject Headings
- Cardiovascular System & Hematology
- 3208 Medical physiology
- 3201 Cardiovascular medicine and haematology
- 1116 Medical Physiology
- 1102 Cardiorespiratory Medicine and Haematology
- 0601 Biochemistry and Cell Biology
Citation
APA
Chicago
ICMJE
MLA
NLM
Rector, T. S., Carson, P. E., Anand, I. S., McMurray, J. J., Zile, M. R., McKelvie, R. S., … Massie, B. M. (2012). Assessment of Long-Term Effects of Irbesartan on Heart Failure With Preserved Ejection Fraction as Measured by the Minnesota Living With Heart Failure Questionnaire in the Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) Trial. Circulation: Heart Failure, 5(2), 217–225. https://doi.org/10.1161/circheartfailure.111.964221
Rector, Thomas S., Peter E. Carson, Inder S. Anand, John J. McMurray, Michael R. Zile, Robert S. McKelvie, Michel Komajda, Michael Kuskowski, and Barry M. Massie. “Assessment of Long-Term Effects of Irbesartan on Heart Failure With Preserved Ejection Fraction as Measured by the Minnesota Living With Heart Failure Questionnaire in the Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) Trial.” Circulation: Heart Failure 5, no. 2 (March 2012): 217–25. https://doi.org/10.1161/circheartfailure.111.964221.
Rector TS, Carson PE, Anand IS, McMurray JJ, Zile MR, McKelvie RS, et al. Assessment of Long-Term Effects of Irbesartan on Heart Failure With Preserved Ejection Fraction as Measured by the Minnesota Living With Heart Failure Questionnaire in the Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) Trial. Circulation: Heart Failure. 2012 Mar;5(2):217–25.
Rector, Thomas S., et al. “Assessment of Long-Term Effects of Irbesartan on Heart Failure With Preserved Ejection Fraction as Measured by the Minnesota Living With Heart Failure Questionnaire in the Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) Trial.” Circulation: Heart Failure, vol. 5, no. 2, Ovid Technologies (Wolters Kluwer Health), Mar. 2012, pp. 217–25. Crossref, doi:10.1161/circheartfailure.111.964221.
Rector TS, Carson PE, Anand IS, McMurray JJ, Zile MR, McKelvie RS, Komajda M, Kuskowski M, Massie BM. Assessment of Long-Term Effects of Irbesartan on Heart Failure With Preserved Ejection Fraction as Measured by the Minnesota Living With Heart Failure Questionnaire in the Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) Trial. Circulation: Heart Failure. Ovid Technologies (Wolters Kluwer Health); 2012 Mar;5(2):217–225.
Published In
Circulation: Heart Failure
DOI
EISSN
1941-3297
ISSN
1941-3289
Publication Date
March 2012
Volume
5
Issue
2
Start / End Page
217 / 225
Publisher
Ovid Technologies (Wolters Kluwer Health)
Related Subject Headings
- Cardiovascular System & Hematology
- 3208 Medical physiology
- 3201 Cardiovascular medicine and haematology
- 1116 Medical Physiology
- 1102 Cardiorespiratory Medicine and Haematology
- 0601 Biochemistry and Cell Biology